Preclinical studies demonstrate that Nor administration attenuates lysosomal exocytosis‐mediated senescence‐associated secretory phenotype (SASP) and reduces aggressive phenotypes in gastric cancer models, underscoring the HOXA1/PITX2 axis as a critical regulator of gastric cancer progression. The gene discussed is PITX2; the disease is gastric cancer.